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Abstract
Background
Infantile spasms represent a serious epileptic syndrome that occurs in the early
infantile age. ACTH and Vigabatrin are actively investigated drugs in its treatment.
This study provides a comparison of their efficacy in a large series of patients with
infantile spasms from Pakistan.
Methods
All patients with infantile spasms who presented to Aga Khan University Hospital,
Karachi, Pakistan from January, 2006 to April, 2008 were included in this study.
Inclusion criteria were clinical symptoms of infantile spasms, hypsarrythmia on
electroencephalography, at least six months of follow-up period and receipt of any
of the two drugs mentioned above. The type of drug distribution was random
according to the availability, cost and ease of administration.
Results
Fifty six cases fulfilled the inclusion criteria. 62.5% were males. Mean age at onset
of seizures was 5 ± 1.4 months. Fifty two (92.8%) patients demonstrated
hypsarrythmia on electroencephalography. 64.3% cases were identified as
symptomatic while 19.6% were cryptogenic and 16.1% were idiopathic. Eighteen
patients received ACTH while 38 patients received Vigabatrin as first line therapy.
Initial response to first line therapy was similar (50% for ACTH and 55.3% for
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Vigabatrin). Overall, the symptomatic and idiopathic groups responded better to
Vigabatrin. The relapse rate was higher for ACTH as compared to Vigabatrin
(55.5%

vs.

33.3%)

when

considering

the

first

line

therapy.

Four patients evolved to Lennox-Gastaut variant; all of these patients had initially
received Vigabatrin and then ACTH.
Conclusion
Vigabatrin and ACTH showed no significant difference in the initial treatment of
infantile spasms. However, patients receiving ACTH were 1.2 times more likely to
relapse as compared to the patients receiving Vigabatrin when considering
monotherapy. We suggest that Vigabatrin should be the initial drug of choice in
patients presenting with infantile spasms. Larger studies from developing countries
are required to validate the therapeutic trends observed in this study.
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Background
Infantile spasms represent a unique and age-specific epilepsy disorder usually
presenting in early infancy. If left untreated, infantile spasms are associated with
devastating neurological results. This severe epilepsy syndrome is often considered
an age-dependent expression of a damaged brain. [1]

The incidence of infantile spasms ranges from 0.25 – 0.6 per 1000 live births. [2]
Electroencephalography (EEG) characteristically demonstrates the hypsarrythmic
pattern. In addition, there is neurodevelopment regression. [3] Infantile spasm may
be seen either alone or in the constellation of West Syndrome. West syndromee
consists of the triad of infantile spasms, an interictal EEG pattern (hypsarrhythmia
or similar pattern), and mental retardation. The key features to diagnosing infantile
spasms are patient history, age, characteristic semiology of seizures, and distinctive
EEG pattern. [3]

These seizures typically present with a triad of lightning (involving the entire
body), nodding (convulsions of the throat and neck flexor muscles) and Salaam or
jackknife attacks (rapid bending of the head and torso forward and simultaneous
raising and bending of the arms). [1, 4] Infantile spasms are distinct from
myoclonic and tonic seizures. They are characterized by a contraction phase
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followed by a more tonic phase. The contraction phase may be a flexor spasm,
extensor spasm, or a combination of both and these could be symmetrical or
asymmetrical
The frequent onset of infantile spasms in infancy suggests that an immature central
nervous system may be important in its pathogenesis. The brain-adrenal axis may
also be involved. It is proposed that the effect of different stressors in the immature
brain produces an abnormally excessive secretion of corticotropin-releasing
hormone (CRH), causing spasms. The clinical response to adrenocorticotropic
hormone (ACTH) and glucocorticoids can be therefore be explained by the
suppression of CRH production. [1]
The treatment of infantile spasms has been both a conundrum and a challenge for
the pediatric neurologist as the entity appears to be resistant to many conventional
antiepileptic drugs. Agents that have been employed in the treatment of infantile
spasms include benzodiazepams (especially nitrazepam), sodium valproate,
vigabatrin (VGB), corticosteroids, ACTH, a ketogenic diet, vitamin B6,
intravenous gammaglobulin, a benzodiazepam-carbamazepine cocktail, topiramate
and zonisamide. [2, 5]
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Currently ACTH and vigabatrin are the actively investigated drugs with some
evidence of efficacy in the treatment of infantile spasms. However, there is little
consensus with regards to the definitive dose, efficacy or duration of treatment of
these agents in comparison to each other. [3] Studies on experience with ACTH
and Vigabatrin from Pakistan and neighboring regions are lacking. To date, there
has been only one study from Pakistan reporting the use of ACTH and
prednisolone. [6] There has been no study exploring the efficacy of Vigabatrin in
Pakistan. Therefore, this study was undertaken to provide an important perspective
on the treatment of infantile spasms in the setting of a developing country like
Pakistan.
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Methods
Study setting
The Aga Khan University Hospital (AKUH) is a tertiary level teaching facility in
the private sector in Karachi, Pakistan. It has approximately 550 beds and provides
services to over 38,000 hospitalized patients and to over 500,000 outpatients
annually. [7] Patients belonging to all socioeconomic classes and from all over
Karachi as well as Pakistan visit to AKUH for treatment.
Study design
A retrospective study was conducted in 56 patients with infantile spasms who
presented to AKUH Consulting Clinic from January, 2006 to April, 2008. Patient
records were reviewed and data was collected on structured proformas.
Inclusion and exclusion criteria
Inclusion criteria included the following:
1. Clinical symptomatology of infantile spasms as elicited by thorough physical
examination and detailed history
2. Accompanying EEG findings at initial EEG (hypsarrythmia or similar pattern on
EEG with almost continuous high voltage multifocal spike and wave discharge and
7

a disorganized /chaotic background)
3. At least six months of follow-up from the time of initial diagnosis
4. Receipt of any of the two drugs mentioned above. The type of drug
administration was according to the availability, cost and ease of administration.
Exclusion criteria used for this study were:
1. All children who were diagnosed to have tuberous sclerosis were excluded since
there is enough evidence in literature of the advantage of Vigabatrin over steroids
in cases of infantile spasms with tuberous sclerosis.
2. Children who had already received any of the investigational drugs prior to their
first encounter were also excluded.
Working definitions
a. Response to therapy

Cases were considered as free from infantile spasms either on the basis of clinical
resolution of spasms or on the basis of both clinical resolution of spasms and EEG
resolution of hypsarrythmia. A follow-up EEG couldn’t be performed in all cases
unfortunately due to financial constraints cited by some parents. Partial response
was considered when the number of spasms was reduced by at least ≥ 50% as
8

compared to the baseline spasms at initial presentation before the administration of
any drug. Patients were categorized as having no response when there was no
change in the number of spasms even after a period of 6 weeks of adequate
therapy.
b. Categories based on etiology

All cases were grouped into three categories. Those cases in which infantile
spasms occurred without any identifiable cause, other neurological signs or
symptoms were considered as idiopathic. Patients who were suspected of being
symptomatic but for whom an underlying structural or biochemical cause could not
be identified were classified as cryptogenic. Cases were considered as symptomatic
when the infantile spasms resulted from an identifiable cause and often where
neurologic features or unequivocal developmental delay preceded the onset of
symptoms. [8]
c. Dosages of medications
The starting dose of Vigabatrin varied from 12.5 to 25 mg/kg/day in all the cases
while the maximum dosage of Vigabatrin during the course of treatment was 150
mg/kg/day. Increments were done every 3-5 days depending on the tolerance of the
patient to the drugs administered. We must mention here that some children
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became extremely lethargic and drowsy after receipt of the medication; therefore
the increments were considerably slower in such children depending on their
clinical state. The maximum dosage of Vigabtrin that was given to all cases
depended on the response observed.
For ACTH, the typical dosage was 40 International Units (IU). However, in 2
children the dosages were increased to a maximum of 80 units as their initial
response was considerably slower.
The children who showed a partial or no response to the initial therapy after the
maintenance doses of either of the two medications for adequate time duration of 6
weeks were then put on a second drug. For example, patients who were initially on
Vigabatrin but failed to show adequate response were put on ACTH. Similarly,
patients who were initially on ACTH but failed to show adequate response were
put on Vigabatrin. Patients who showed response to the initial drug were
maintained on that therapeutic agent.
Data management and statistical analysis
The data was coded, entered and analyzed using Windows SPSS version 16.0. In
descriptive analysis, the mean and standard deviations of the continuous variables
and percentages of categorical variables were computed. Associations were
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assessed using chi-square test and Fisher’s exact test where appropriate. A p-value
of < 0.05 was considered statistically significant, unless otherwise specified.
Variables with a significant p-value were further subjected to multiple logistic
regression analysis to ascertain independent predictors of infantile spasm free final
outcome of treatment.
Ethical considerations
Being a retrospective study, the study protocol was granted exemption from review
as per guidelines of the Ethical Review Committee (ERC) of the Aga Khan
University Hospital, Karachi. Informed consent was not needed owing to the
anonymous presentation of the patient data as per guidelines of the ERC at AKUH.
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Results
Fifty six children with infantile spasms were administered either Vigabatrin or
ACTH from 2006-2008. Apart from these 56 patients, an additional two patients
had been given prednisolone as initial treatment for infantile spasms. Although
they showed complete resolution of the infantile spasms, they were not included as
part of primary analysis due to insufficient numbers.
Clinical profile of patients
a. Baseline characteristics
The baseline characteristics of our sample are presented in Table 1. The majority
of the patients were male (35/56, 62.5%). Twelve patients (21.4%) were small for
gestational age with a birth weight of less than 2.5 kg. A family history of
abortions and stillbirths was present in 3 patients (5.3%). A history of neonatal
deaths in the family was found in 4 cases (7.1%); however, the definitive cause of
death was not known. Three patients (5.3%) had a family member with mental
retardation and developmental delay. A family history of infantile spasms was not
present in any child. Antenatally, mothers of 3 patients had a history of
oligohydramnios during gestation, 2 had a history of typhoid fever (blood culture
proven) in the first trimester, and 2 had a history of chorioamnionitis (clinical
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diagnosis) in the third trimester. Two mothers also had a history of self-resolving
heaving bleeding in the first trimester. On presentation 37/56 (66%) children had a
fronto-occipital circumference (FOC) less than 5th centile. Four children (7.1%)
had brachycephaly on examination. All the patients received an initial EEG. Fifty
two (92.8%) patients exhibited the classic hypsarrythmic pattern while a similar
pattern such as modified hypsarrythmia was less commonly seen (7.2%). Of the 58
cases of infantile spasms, forty two (75%) patients had not received any prior antiepileptic medications. The remaining had been treated as non-specific seizure
disorder before presenting to our hospital.
b. Etiology of infantile spasms
In our patient population, 36 (64.3%) of the cases of infantile spasms were
symptomatic while 11 (19.6%) were cryptogenic and the remaining 9 cases were
idiopathic (16.1%). The criteria used for classifying the cases into symptomatic,
cryptogenic and idiopathic types have been mentioned in detail in the Methods
section above. Among the symptomatic cases, cerebral palsy secondary to birth
asphyxia was identified as the leading cause of infantile spasms (Table 2).It was
seen that almost 51.8% (29/56) patients had a history of delayed cry at birth. As
per parental recall, the mean time for cry after birth was 7.5 ± 3.5 minutes.
APGAR scores were not available in most of the cases since the deliveries since
the deliveries had been performed outside our hospital.
13

Treatment and outcomes
a. Initial therapy of infantile spasms
All patients were given one medication at any given time. Out of 56 patients, 18
patients (32.1%) received ACTH while 38 patients (67.9%) received Vigabatrin as
initial therapy. The results of initial therapy are presented in Table 3. Initially, 9
out of 18 (50%) patients completely responded to ACTH monotherapy while 21
out of 38 (55.3%) patients completely responded to Vigabatrin monotherapy
initially.
b. Switch to second drug
As mentioned above, 50% and 44.7% patients initially on ACTH and Vigabatrin
therapy didn’t show adequate response to therapy even after 6 weeks duration.
These were patients who showed either partial or no response to the initial therapy.
They were then put on a second and different drug. Patients initially on ACTH
were now put on Vigabatrin and vice versa. The response of patients to the second
drug is shown in table 4.
c. Relapse
Even among patients who had shown complete resolution of seizures after therapy,
some experienced relapse. Fifty percent patients initially put on ACTH showed full
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response. However, 5 out of these 9 patients (55.6%) relapsed. Similarly, 21
patients had shown full response to Vigabatrin initially. However, 7 out of these 21
patients (33.3%) relapsed. The relapse rate was higher for ACTH as compared to
Vigabatrin (55.5% against 33.3%) when considering the initial monotherapy.
The average time for relapse and complete cessation of seizures also yielded
interesting findings. It was observed that the patients started on ACTH had earlier
relapses and delayed recovery (both clinically and based on EEG findings), as
opposed to those started on Vigabatrin therapy. These time durations were 2 weeks
for the former and 2 months for the later. Those who were switched to Vigabatrin
after prior ACTH therapy relapsed after 6 months on average as opposed to those
who were switched to ACTH therapy after prior Vigabatrin therapy, who relapsed
after an average time of 2 months. (Table 5) Patients receiving ACTH were 1.2
times more likely to relapse as compared to the patients receiving Vigabatrin when
considering monotherapy.
d. Final outcome of patients
At the time of last follow-up, the cumulative outcome was based either on EEG
findings, and / or clinical signs and seizure activity. (Table 5) Only four of the
patients initially on ACTH and 14 of the patients initially on Vigabatrin remained
seizure free at last follow-up and had not experienced any relapse. Among those
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who were started on the second drug after incomplete or no response to the first
drug, 93% of those on ACTH and 73% of those on Vigabatrin therapy continued to
have seizures. It was observed that 4 patients out of the 24 patients who had
received ACTH as the second drug evolved to Lennox-Gastaut variant.
The association of the outcome at the last follow-up was significant for the type of
treatment received (p < 0.001), the etiology of infantile spasms (p < 0.001) and the
age at diagnosis of infantile spasms (p=0.04). The association of final outcome
with age at onset seizures was not significant (p=0.869). For outcome at last
follow-up in terms of clinical and electroencephalographic resolution of seizures,
the following variables were subjected to multiple logistic regression analysis: type
of treatment received, etiology of infantile spasms and age at diagnosis. (Table 6)
It was seen that response to first line treatment, etiology other than symptomatic
and younger age at diagnosis are factors associated with resolution of seizures.
e. Association of response to first line therapy with etiology
Considering the seizure outcome with respect to the etiology, it was seen that 30%
of all the patients in the symptomatic group responded to monotherapy. Sixty
percent of this response was due to Vigabatrin while 34% was due to ACTH. In the
cryptogenic group, 36% patients responded to first line therapy. Distribution of this
response to first line therapy was 55% and 45% due to Vigabatrin and ACTH
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respectively. In the idiopathic group, almost 50% patients responded to first line
therapy. Vigabatrin accounted for all the responsive cases of idiopathic group with
regards to first line therapy.

f. Side effects of therapy
Comparing the side effect profile of the drugs, 6 patients developed ACTH induced
hypertension while 1 patient developed Vigabatrin induced rash. One patient
developed visual field defects secondary to Vigabatrin. However, many patients
did not get a complete and detailed eye examination done (including visually
evoked potentials and other studies) after being put on Vigabatrin therapy due to
non-availability of retinograms at our institution.
g. Mortality
A total of 4 patients expired in this study; 2 were receiving vigabatrin at the time of
death and their death was attributed to aspiration pneumonia. The remaining 2
were on ACTH therapy and their death was attributed to septicemia. All 4 cases
were of symptomatic category of infantile spasms.
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Discussion
Infantile spasms were first described 160 yeas ago in a letter that Dr West wrote to
Lancet. [9] Since then atleast 30 drugs have been investigated in the treatment of
infantile spasms, but hitherto, no definitive universal standard exists for the
treatment of infantile spasms. Our study provides a developing world perspective
on the treatment of infantile spasms with particular reference to two drugs:
Vigabatrin and ACTH. First line therapy consisted of either ACTH or Vigabatrin
in this study. A second drug was started if the patients showed partial or no
response to one of the first line agents. At any given time in the study, patients
were put on not more than one drug.
Birth asphyxia
Cerebral palsy secondary to birth asphyxia / hypoxic ischemic encephalopathy was
identified as the leading cause of infantile spasms in our study, contributing to
almost 70% of the symptomatic cases. The diagnosis was primarily based on
history, neurological examination and brain imaging. The spectrum of underlying
etiologies in our study was quite similar to other studies. In a large study, one-third
of symptomatic patients had birth related etiology. [10] In another study, hypoxic
ischemic encephalopathy was the commonest underlying etiology. [11] According
to data from the World Health Organization, 4 – 9 million babies develop birth
18

asphyxia per year and of these, more than 1 million die and roughly the same
number develop neurological sequelae. [12] Data from Pakistan has shown that it
is one of the leading causes for admission in a neonatal unit. [13] An analysis of
neonatal mortality and morbidity in Pakistan has shown that most causes of
neonatal morbidity in Pakistan are preventable. [14] In a study conducted in
Pakistan, it was reported that lack of antenatal care in mothers, delivery by
unskilled birth attendants either at home or a private health facility and prolonged
labour were significant risk factors for asphyxial insult at birth. [15, 16] Similarly,
another study from Pakistan has reported the association between lack of antenatal
care, poor nutritional status of mother and antepartum hemorrhage with higher
incidence of birth asphyxia. [17] Birth asphyxia may thus be a reflection of the
unhealthy baseline maternal status as well as the poor perinatal services offered in
maternity homes, communities or hospitals. [18] In order to ameliorate the
situation, increased coverage of the population by high quality health services and
skilled birth attendants is imperative. [19, 20] Evidence based and cost-effective
resuscitation strategies for neonates should be implemented. [21] Improvements in
proximal risk factors such as female nutrition and prompt treatment as well as
prevention of infections should be the long term goals of any policy geared
towards improving maternal and child health. [17, 21] Similarly, improvement in
maternal education should be made a priority in both urban and rural settings.
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Therapeutic parameters
No statistically significant difference was observed between the response rates
(based on clinical observation and resolution on EEG when available) of patients
put on either ACTH or Vigabatrin therapy initially. Responses to both the first and
the second drug were also almost similar, as obvious from the p-values derived
from chi-square or fisher’s exact testing. However, taking the final outcome at the
time of last follow-up into account, it was seen that overall employment of
monotherapy prognosticated better remission rates as compared to patients who
received a second drug as add-on therapy. It was observed that the majority of the
patients who responded to treatment did so within the first few weeks of being put
on therapy. However, a full 6 weeks of therapy was allowed in our study before
switching to the second drug.
The United Kingdom infantile spasms study comparing vigabatrin with
prednisolone or tetracosactide at 14 days was a multicentred randomized controlled
trial where the primary outcome was cessation of spasms at day 13 and 14. [22]
According to the study, there was more likelihood of cessation of spasms at day 14
in infants given hormonal treatment than those given Vigabatrin. We didn’t
observe similar results in our study. Our period of treatment extended well beyond
the 14 days parameter used in this study.
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Even though younger age at onset has been associated with a worse prognosis [9],
but the results in our study were inconsistent with this finding, where younger age
at diagnosis appeared to portend better chances of resolution of infantile spasms.
We believe that it is possible that earlier diagnosis at a younger age led to earlier
administration of therapy which may have led to improved outcomes.
When compared in terms of complete cessation of seizures, both ACTH and
Vigabatrin monotherapy as well as add-on therapy showed average cessation rates
ranging between 20% and 50%. The results for Vigabatrin are consistent with a
class I randomized placebo-controlled trial, which reported 35% response rate. [23]
In another large study, 21% to 44% patients responded to Vigabatrin therapy. [24]
Our results for ACTH are not in agreement with a meta-analysis that showed a
cessation rate ranging from 54% to 100%. [25] Several other studies also report
similar results. [26, 27] One reason for this inconsistency could be that the
aforestated studies have used higher starting doses for ACTH, with 75 IU being the
most common dose, as opposed to our study, where the starting dose for 40 IU in
almost all cases. This can be further substantiated by two studies that report that
ACTH was effective at higher doses, based both on response rate and plasma
hormone data. [6, 28 - 30]
Overall prognosis in our study was poor. After the onset of spasms, 52/56 (92.8%)
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children showed developmental delay while only 4 children (7.2%) showed normal
developmental milestones. Most of the reports from other countries also report
poor outcome in infantile spasms. [27]
Considering the final seizure free outcome, etiology and treatment used, it was
seen that idiopathic group and symptomatic groups responded well to Vigabatrin as
compared to ACTH. These results are consistent with earlier performed studies. In
one retrospective study, it was seen that symptomatic children with developmental
brain lesions responded at a rate of 83% to vigabatrin versus 63% for ACTH.
Cryptogenic spasms responded at a similar rate to both drugs as was seen in our
study. [31]

With regards to the side-effect profile, Vigabatrin was better than ACTH; with
only two patients experiencing the adverse effects, as opposed to ACTH, where six
patients reported ACTH-induced hypertension. A previous study has reported
arterial hypertension in 11 out of 162 children (6.8%) on ACTH therapy. Mortality
in this study has been stated as 4.9%. The other mentioned side effects included
infections (being the most common), followed by marked electrolyte disturbances
(10 patients), osteoporosis (2 patients), and hypokalaemic alkalosis (2 patients).
[32] Septicemia was the cause of death in both of our patients on ACTH therapy as
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mentioned above. Vigevano and Cilio have reported hormonal treatments to have
greater adverse effects and thus a higher potential to induce mortality. [23]
However, in our study, detailed visual field examination could not be carried out in
every child receiving Vigabatrin because of financial constraints. This may have
lead to underestimation of the side effects of Vigabatrin. Recent reports have
established that eye changes occur in patients treated with vigabatrin. A
prospective study reports that most children with epileptic syndromes on vigabatrin
cannot complain of their eye problems, hence 3-6 monthly ophthalmic follow up is
strongly advised, along with regular electroretinography, electro-oculography, and
visual evoked potentials if possible. [33] A study from Oman reports one death in a
patient on vigabatrin therapy due to aspiration pneumonia. [34] Currently, the
benefits of treating infantile spasms with vigabatrin monotherapy seem to
outweigh the risks, but further prospective studies and follow-up of children
receiving treatment are needed to evaluate the place of vigabatrin in this indication.
[35] It is concluded that side effects, even severe ones, are more common during
treatment than had been assumed. Careful watch is important before and after
treatment. The benefit of very high dosages should also be reconsidered. [32] The
side effect profile of vigabatrin dictates that children be started on therapy with a
concomitant short admission to the hospital for better observation and institution of
aspiration precautions. This, however, has important implications for a developing
23

country like Pakistan where scarce resources are expended on child health care.

Four patients in our study developed Lennox Gastaut Syndrome (LGS) while on
therapy. All of these patients had received Vigabatrin initially and had then been
put on ACTH. A study from Finland reports 27% of patient with infantile spasms
eventually evolving to LGS. [36, 37] A review article reported that 20% of all
patients with LGS have prior infantile spasms with hypsarrythmia. [38] LGS
seizures are often treatment resistant and the long term prognosis is poor. [28]
However, we did not come across any study that reports the association of children
with infantile spasms on a particular therapy subsequently evolving to LGS.

During 2006 – 2008, we had treated two patients of infantile spasms with
prednisolone at a dose of 1.5 mg/kg/day. Although this dose of prednisolone was
lower than that used in UKISS study (4 mg/kg/day), it resulted in resolution of
spasms. While the demonstration of this aspect with such small numbers is
insufficient for analysis or derivation of conclusions, it may be studied further in
the future for better validation.
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Strengths and limitations
Literature on pediatric neurology is generally under-represented from the
developing countries. In particular, studies on experience with ACTH and
Vigabatrin in the treatment of infantile spasms are lacking. Therefore, this study is
an important perspective on the management of infantile spasms in the setting of a
developing country. To the best of our knowledge, this is the first study of its kind
in Pakistan to compare Vigabatrin and ACTH as treatment options for infantile
spasms.
However, we acknowledge the following limitations of our study. Conclusions
derived from it should be interpreted with these limitations in mind. The study was
based on a retrospective chart review. This study design has its inherent
weaknesses and is not as robust as a prospective study. Our source of data was
restricted to hospital records which in turn were reflecting an objective assessment
by the physician as well as reliance on parental descriptions for accounts of spasms
and seizures. These may not be bias free or accurately recalled in every instance.
Secondly, the election of treatment was based on several factors such as
availability, cost and ease of administration. The groups were not randomized. As a
result, twice as many patients received Vigabatrin as compared to ACTH. Thirdly,
there was no wash out period between the cessation of first drug and initiation of
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second drug. The wash-out period was not a feasible option either because many of
these children were seizing at the time the drugs were switched. We do
acknowledge that a confounding effect may have been introduced because of this
approach. All patients didn’t get serial EEGs done. In particular, control EEGs
were not available for all patients during follow-up. We had divided the groups
into symptomatic, cryptogenic and idiopathic. Patients who were suspected of
being symptomatic but for whom an underlying structural or biochemical cause
could not be identified were classified as cryptogenic. Although patients were
evaluated clinically and radiologically while such categorization was done, MRI
scans were not performed in all patients due to financial constraints and CT scans
were used in some patients as a less expensive alternative. MRI studies are
important for defining the cryptogenic groups further.
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Conclusion
Vigabatrin was found to be more efficacious in the treatment of the symptomatic
and the idiopathic type of infantile spasm. However, Vigabatrin and ACTH
showed no significant difference in the initial treatment of infantile spasms. These
results are consistent with the findings stated in the practice parameter published in
2004 in Neurology by the American academy of Neurology (AAN) and Child
Neurology Society that bases its recommendations for the treatment of infantile
spasms on two large surveys conducted in the US and Japan. [25] Patients
receiving ACTH were 1.2 times more likely to relapse as compared to the patients
receiving Vigabatrin when considering monotherapy. Younger age at diagnosis of
infantile spasms portends resolution of seizures as compared to older age. Larger
studies are required to validate the therapeutic trends observed in our study. Birth
asphyxia, a potentially preventable condition, was a leading etiology of
symptomatic infantile spasms in our study. We need to gear efforts towards
reducing the incidence of birth asphyxia in our part of the world through carefully
tailored strategies. This will have an enormous impact by reducing a preventable
cause of symptomatic infantile spasms. Despite all the advances in understanding
the various treatment options available, infantile spasms still remains an elusive
childhood disease that is difficult to treat with the overall prognosis being dismal.
The search for an ideal drug therefore continues – a drug that is not only effective
27

in controlling spasms, has minimal side effects and improves long term outcome,
but is also easily accessible to most patients. [6]
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Tables

Table 1: Baseline characteristics of patients presenting with infantile spasms

Characteristics of patients with infantile spasms

n=56 (%)

Age of onset of seizures in months (Mean ± SD)

5 ± 1.4

Age at diagnosis of infantile spasms in months (Mean ± SD)

6.5 ± 2.3

Lag interval between onset and diagnosis in months (Mean ± SD)

1.4 ± 1.3

Gender (male)

35 (62.5%)

Consanguinity of parents

19 (33.9%)

Seizures per day at onset (Mean ± SD)

62 ± 5.1

Clusters per day at onset (Mean ± SD)

21 ± 4.2

Type of spasms

-Flexion

23 (41.1%)

-Extension

6 (10.7%)

-Mixed

15 (26.8%)

History of neonatal seizures

15 (26.8%)

History of stay in neonatal intensive care unit

14 (25%)

History of premature birth (< 37 weeks gestation)

14 (25%)

History of neonatal sepsis / meningitis

10 (17.8%)

History of developmental delay prior to onset of symptoms

41 (73.2%)
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Table 2: Etiology of Symptomatic Infantile Spasms

Etiology of symptomatic cases of infantile spasms

% (n=36)

Birth asphyxia

69.4

Complication of pre-maturity

11.1

Post maturity (> 41 weeks gestation)

2.8

Aicardi Syndrome

2.8

Bilirubin encephalopathy (kernicterus)

2.8

Inborn error of metabolism ^

5.5

Post meningitic sequalae

2.8

^ Urea cycle defect and Glutaric Acid deficiency were identified
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Table 3: Response of patients to initial therapy
Patient Response to Initial Therapy
(p=0.696)

ACTH

Vigabatrin

n=18 (%)

n=38 (%)

-Complete cessation

9 (50)

21 (55.3)

-Partial response

6 (33.3)

10 (26.3)

-No response

3 (16.7)

7 (18.4)
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Table 4: Response of patients to second drug that was administered after 6 weeks
in case of partial or no response to first drug
Patient Response to Second Drug
(p=0. 334)

ACTH ^

Vigabatrin ^^

n=17 (%)

n=9 (%)

-Complete cessation

5 (29.4)

2 (22.2)

-Partial response

5 (29.4)

5 (55.6)

-No response

7 (41.2)

2 (22.2)

^ Patients who had initially received Vigabatrin and shown partial or no response
to it
^^ Patients who had initially received ACTH and shown partial or no response to
it.
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Table 5: Final outcome at last follow-up
Therapy

Seizure free

Continued to

till last follow-up

have seizures

ACTH

Ave. relapse Ave. recovery
time

time^

Evolved to
Lenox Gestaut variant*

4

0

2 wks

2 months

0

14

0

2 months

1 month

0

1

13

6 months

3 months

0

2

18

2 months

6 months

4

monotherapy
(n=4) ^^
Vigabatrin
monotherapy
(n=14) ^^
ACTH followed
by Vigabatrin
(n=14)
Vigabatrin followed
by ACTH (n=24)

^ Average time to complete recovery, if occurred
^^ Remained on monotherapy till the last follow-up and didn’t receive any second
drug
* Evolution by 2 years
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Table 6: Multiple logistic regression analysis showing predictors for final outcome
of infantile spasms in terms of resolution of seizures

Variables

Resolution of Seizures (EEG and/or clinical)
Adjusted OR *

95% CI **

Type of therapy (p < 0.001)
Receipt of second drug

1

-

ACTH monotherapy

4.2

0.6 – 6.8

Vigabatrin monotherapy

4.6

1.1 – 7.2

Etiology (p < 0.001)
Symptomatic

1

-

Cryptogenic

1.2

0.4 – 2.1

Idiopathic

4.4

1.6 – 6.9

1

-

6 – 12 months

1.2

0.8 – 1.5

< 6 months

1.3

0.6 – 2.1

Age at Diagnosis (p=0.04)
> 12 months

* OR = Odds Ratio
** CI = Confidence Interval
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